FDA to review Durect pain product

Durect Corp. (NASDAQ:DRRX) said FDA accepted for review an NDA for Posidur to treat post-operative pain. The PDUFA date is Feb. 12, 2014. The NDA was submitted under section 505(b)(2) of the Food, Dru...